Table 1.
Demographic and baseline characteristics of analysis population at baseline (mITT, n=224)
| Age (years, median and IQR) | 37.7 (29.2–49.9) | |
| Duration of current symptoms (% (n)) | ||
| <7 days | 13.4 (30) | |
| ≥7 days | 86.6 (194) | |
| Sex | ||
| Female | 46.0 (103) | |
| Time since diagnosis (months, median and IQR) | 52.4 (11.1–128.0) | |
| Current medication (% (n)) | Therapy >7 days | Therapy ≤7 days |
| Systemic steroids | 8.5 (19) | 15.2 (34) |
| AZA/6-MP | 2.2 (5) | 10.7 (24) |
| Anti-TNF | 13.8 (31) | 5.8 (13) |
| Anti-integrin | 7.6 (17) | 0.4 (1) |
| Objective signs of inflammation | Normal values for lab results | |
| (Median and IQR) | ||
| SCCAI (n=224) | 9.0 (7.0–10.0) | |
| Haemoglobin (g/L, n=203) | 131 (116–141) | 115–164 (female), 135–180 (male) |
| Platelets (/mm³, n=202) | 338 000 (265 000–430 000) | 150 000–300 000 |
| WCC (/x109/L, n=201) | 8.8 (7.39 – 11.3) | 4.4–11.3 |
| CRP (mg/dL, n=196) | 1.30 (0.58–4.46) | <0.5 |
| Feacal calprotectin | ||
| (µg/g, median and IQR) | 800 (439–1436) | |
| <250 (µg/g) | 9.9% (14) | |
| ≥250 (µg/g) | 90.1% (128) | |
| Bowel wall thickness | ||
| (mm, median and IQR) | ||
| Sigmoid colon (n=218) | 5.05 (4.60–6.20) | |
| Descending colon (n=198) | 5.00 (4.00–6.00) |
AZA, azathioprine; CRP, C reactive protein; mITT, modified intention-to-treat; MP, mercaptopurine; SCCAI, Short Clinical Colitis Activity Index; TNF, tumour necrosis factor; WCC, white cell count.